Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19 : Rationale, Clinical Evidence and Risks
The epidemic due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has been spreading globally, raising increasing concerns. This public health emergency has triggered a race to find medications to improve the prognosis of this disease. There is currently great interest in drug repositioning to manage SARS-CoV-2 infection, that is, the evaluation of the potential benefits of a drug that has already been proven safe and effective in humans for other approved indications. As interleukin-6 (IL-6) acts as a key driver of the inflammation associated with coronavirus disease 2019 (COVID-19), IL-6 and IL-6 receptor (IL-6R) inhibition appear to be promising targets for the treatment of COVID-19 patients. It is important to critically analyze the available evidence concerning the use of the available anti-IL-6 (siltuximab) and anti-IL-6R (tocilizumab and sarilumab) agents in COVID-19 patients, in terms of both benefit and risk. In this review, the pathogenesis of the cytokine storm induced by COVID-19, the role of IL-6 in this cytokine storm, the rationale for the use of anti-IL-6 agents, and key information on potential benefits and safety monitoring of these biologicals in COVID-19 patients is discussed.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
---|---|
Enthalten in: |
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy - 34(2020), 4 vom: 18. Aug., Seite 415-422 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Crisafulli, Salvatore [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antibodies, Monoclonal |
---|
Anmerkungen: |
Date Completed 06.08.2020 Date Revised 18.02.2022 published: Print Citation Status MEDLINE |
---|
doi: |
10.1007/s40259-020-00430-1 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM311359027 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM311359027 | ||
003 | DE-627 | ||
005 | 20231225142101.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s40259-020-00430-1 |2 doi | |
028 | 5 | 2 | |a pubmed24n1037.xml |
035 | |a (DE-627)NLM311359027 | ||
035 | |a (NLM)32557214 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Crisafulli, Salvatore |e verfasserin |4 aut | |
245 | 1 | 0 | |a Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19 |b Rationale, Clinical Evidence and Risks |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 06.08.2020 | ||
500 | |a Date Revised 18.02.2022 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a The epidemic due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has been spreading globally, raising increasing concerns. This public health emergency has triggered a race to find medications to improve the prognosis of this disease. There is currently great interest in drug repositioning to manage SARS-CoV-2 infection, that is, the evaluation of the potential benefits of a drug that has already been proven safe and effective in humans for other approved indications. As interleukin-6 (IL-6) acts as a key driver of the inflammation associated with coronavirus disease 2019 (COVID-19), IL-6 and IL-6 receptor (IL-6R) inhibition appear to be promising targets for the treatment of COVID-19 patients. It is important to critically analyze the available evidence concerning the use of the available anti-IL-6 (siltuximab) and anti-IL-6R (tocilizumab and sarilumab) agents in COVID-19 patients, in terms of both benefit and risk. In this review, the pathogenesis of the cytokine storm induced by COVID-19, the role of IL-6 in this cytokine storm, the rationale for the use of anti-IL-6 agents, and key information on potential benefits and safety monitoring of these biologicals in COVID-19 patients is discussed | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
650 | 7 | |a Interleukin-6 |2 NLM | |
650 | 7 | |a Receptors, Interleukin-6 |2 NLM | |
650 | 7 | |a tocilizumab |2 NLM | |
650 | 7 | |a I031V2H011 |2 NLM | |
650 | 7 | |a sarilumab |2 NLM | |
650 | 7 | |a NU90V55F8I |2 NLM | |
650 | 7 | |a siltuximab |2 NLM | |
650 | 7 | |a T4H8FMA7IM |2 NLM | |
700 | 1 | |a Isgrò, Valentina |e verfasserin |4 aut | |
700 | 1 | |a La Corte, Laura |e verfasserin |4 aut | |
700 | 1 | |a Atzeni, Fabiola |e verfasserin |4 aut | |
700 | 1 | |a Trifirò, Gianluca |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy |d 1997 |g 34(2020), 4 vom: 18. Aug., Seite 415-422 |w (DE-627)NLM096446870 |x 1179-190X |7 nnns |
773 | 1 | 8 | |g volume:34 |g year:2020 |g number:4 |g day:18 |g month:08 |g pages:415-422 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40259-020-00430-1 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 34 |j 2020 |e 4 |b 18 |c 08 |h 415-422 |